TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34197699

Group type: EXPERIMENTAL
Intervention: Pharmacist-led medication therapy monitoring and management via a smartphone-enabled mHealth app
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual posttransplant care (Control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacist-led intervention
Number of subjects: 0
Study: 34821175

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy (cisplatin with pemetrexed)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus chemotherapy (cisplatin with pemetrexed)
Number of subjects: 66
Study: 32799960

Group type: EXPERIMENTAL
Intervention: Chronic mucosal disease group
Number of subjects: 67

Group type: COMPARATOR
Intervention: Chronic squamous disease group
Number of subjects: 67
Study: 616411671

Group type: EXPERIMENTAL
Intervention: Biosimilar CT-P13
Number of subjects: 0

Group type: COMPARATOR
Intervention: Originator infliximab
Number of subjects: 0
Study: 36420937

Group type: EXPERIMENTAL
Intervention: PFMT + EA
Number of subjects: 304

Group type: COMPARATOR
Intervention: PFMT + sham EA
Number of subjects: 304
Study: 34895064

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive-Behavioral Sex Therapy (MBCST)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study: 35817672

Group type: EXPERIMENTAL
Intervention: Bivalirudin (1 mg/kg bolus followed by 2.5 mg/kg/h infusion, adjusted to maintain ACT >480 s)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Bivalirudin (1 mg/kg bolus followed by 2.2 ± 0.4 mg/kg/h infusion)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 25
Study: 34593526

Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy (SABR)
Number of subjects: 89
Study: 35272050

Group type: EXPERIMENTAL
Intervention: Contoured foot orthoses
Number of subjects: 88

Group type: COMPARATOR
Intervention: Sham flat insoles
Number of subjects: 88
Study: 32151792

Group type: EXPERIMENTAL
Intervention: Illusory patterns with vertically aligned white dots in T shape
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Illusory patterns with vertically aligned white dots in L shape
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison of T shape vs L shape configurations
Number of subjects: 0
Study: 33883508

Group type: EXPERIMENTAL
Intervention: Cytokine adsorption (CytoSorb)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control (no cytokine adsorption)
Number of subjects: 46
Study: 32428786

Group type: EXPERIMENTAL
Intervention: Exercise training, nutritional education, and medication reconciliation for 5.1 ± 0.6 months
Number of subjects: 391
Study: 35616942

Group type: EXPERIMENTAL
Intervention: Spermidine supplementation (0.9 mg spermidine/d) for 12 months
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (microcrystalline cellulose) for 12 months
Number of subjects: 100
Study: 33564824

Group type: EXPERIMENTAL
Intervention: Folic acid (800 µg daily for 3 years)
Number of subjects: 791
Study: 35277080

Group type: EXPERIMENTAL
Intervention: Potato dishes (POT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Refined grain dishes (REF)
Number of subjects: 50
Study: 32857212

Group type: EXPERIMENTAL
Intervention: Automated ASPECTS software
Number of subjects: 459

Group type: COMPARATOR
Intervention: Observers
Number of subjects: 459
Study: 32748994

Group type: EXPERIMENTAL
Intervention: Inpatient evaluation
Number of subjects: 2060

Group type: COMPARATOR
Intervention: Outpatient testing (early emergency room discharge)
Number of subjects: 2060
Study: 35173154

Group type: EXPERIMENTAL
Intervention: penicillin + gentamicin
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: co-amoxiclav + gentamicin
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: amoxicillin + cefotaxime
Number of subjects: 147

Group type: COMPARATOR
Intervention: non-antibiotic treated infants (control group)
Number of subjects: 147
Study: 35868622

Group type: EXPERIMENTAL
Intervention: Primary IOL implantation
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Measured anterior chamber depth (ACD) used to calculate predicted refraction
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Multiple regression analysis
Number of subjects: 43
Study: 34480008

Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate (SB; 0.3 g/kg body mass) with HI warm-up
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate (SB; 0.3 g/kg body mass) with LI warm-up
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (PLA; maltodextrin) with HI warm-up
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (PLA; maltodextrin) with LI warm-up
Number of subjects: 12
Study: 36147018

Group type: EXPERIMENTAL
Intervention: CBMT + TAU (Cognitive Bias Modification Training + Treatment as Usual)
Number of subjects: 67

Group type: COMPARATOR
Intervention: TAU (Treatment as Usual)
Number of subjects: 67
Study: 33023750

Group type: EXPERIMENTAL
Intervention: Bolus feeding regimen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continuous feeding regimen
Number of subjects: 0
Study: 34819195

Group type: EXPERIMENTAL
Intervention: Machine learning models (elastic net regressions and random forests)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Traditional models (logistic/linear regressions)
Number of subjects: 191
Study: 34212998

Group type: EXPERIMENTAL
Intervention: C Mac D‐Blade videolaryngoscope
Number of subjects: 56

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 56
Study: 35191430

Group type: EXPERIMENTAL
Intervention: Endoscopic Papillary Large Balloon Dilation (EPLBD)
Number of subjects: 180
Study: 33688836

Group type: EXPERIMENTAL
Intervention: Revised invitation strategy with prenotification postcard (Group 2)
Number of subjects: 4633

Group type: EXPERIMENTAL
Intervention: Revised invitation strategy with prenotification postcard (Group 3)
Number of subjects: 4633

Group type: EXPERIMENTAL
Intervention: New invitation without prenotification postcard (Group 4)
Number of subjects: 4633

Group type: COMPARATOR
Intervention: Original invitation (Control Group 1)
Number of subjects: 4633

Group type: EXPERIMENTAL
Intervention: Overall participation rate
Number of subjects: 4633

Group type: EXPERIMENTAL
Intervention: Comprehensibility of invitations
Number of subjects: 4633
Study: 33110020

Group type: EXPERIMENTAL
Intervention: Nabiximol (cannabis extract)
Number of subjects: 0
Study: 35212286

Group type: EXPERIMENTAL
Intervention: Probiotics (Bifidobacterium longum NT strain 1010 CFU/day)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Synbiotics (Bifidobacterium longum NT strain 1010 CFU/day and galactooligosaccharide 1 g/day)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control (placebo foods containing vehicle only)
Number of subjects: 69
Study: 32561467

Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy (NET) addressing PTSD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Motivational interviewing with cognitive behavioral therapy skills training (MIST) addressing substance misuse
Number of subjects: 0
Study: 35724489

Group type: EXPERIMENTAL
Intervention: Smartphone application of diabetes coaching intervention (12 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care from community health centers
Number of subjects: 0
Study: 32556709

Group type: EXPERIMENTAL
Intervention: HRV-Biofeedback (HRV-Bfb)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Mindfulness-based interventions (MBI)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Wait-list control group (WLC)
Number of subjects: 69
Study: 34330458

Group type: EXPERIMENTAL
Intervention: Ursolic acid (UA) supplementation (450 mg/day)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 26
Study: 33048901

Group type: EXPERIMENTAL
Intervention: Nonsedation with sufficient analgesia
Number of subjects: 205

Group type: COMPARATOR
Intervention: Light sedation with a daily wake‐up call
Number of subjects: 205
Study: 35779065

Group type: EXPERIMENTAL
Intervention: DHEAS levels
Number of subjects: 34
Study: 33813345

Group type: EXPERIMENTAL
Intervention: Dove Confident Me intervention (five sessions facilitated by trained psychologists)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Lessons-as-usual (control)
Number of subjects: 166
Study: 36163254

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MP; 60 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 0
Study: 33413144

Group type: EXPERIMENTAL
Intervention: Additional resistance and balance training (3 d/wk)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Usual care phase‐II‐CR inpatient multidisciplinary CR program
Number of subjects: 116
Study: 32087001

Group type: EXPERIMENTAL
Intervention: Cenobamate single-dose (5 to 750 mg)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Cenobamate multiple-dose (50 to 600 mg/day)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Cenobamate (all doses)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Cenobamate (multiple daily doses of 600 mg)
Number of subjects: 210
Study: 36017875

Group type: EXPERIMENTAL
Intervention: Obinutuzumab consolidation therapy
Number of subjects: 48

Group type: COMPARATOR
Intervention: No consolidation
Number of subjects: 48

Group type: COMPARATOR
Intervention: Monitoring group (MRD-negative patients)
Number of subjects: 48
Study: 33587687

Group type: EXPERIMENTAL
Intervention: Ad26.ZIKV.001 (5 × 10^10 vp)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ad26.ZIKV.001 (1 × 10^11 vp)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ad26.ZIKV.001 (1 × 10^11 vp, 1-dose regimen)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 34973081

Group type: EXPERIMENTAL
Intervention: Esketamine/antidepressant
Number of subjects: 702

Group type: EXPERIMENTAL
Intervention: Esketamine
Number of subjects: 702
Study: 34523035

Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen cannula (HFNC)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Noninvasive mechanical ventilation (NIV)
Number of subjects: 222
Study: 32589319

Group type: EXPERIMENTAL
Intervention: My Baby's First Teacher intervention
Number of subjects: 45

Group type: COMPARATOR
Intervention: Care-as-usual (control)
Number of subjects: 45
Study: 36084200

Group type: COMPARATOR
Intervention: iTAB
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: iTAB+MI
Number of subjects: 255
Study: 33373701

Group type: EXPERIMENTAL
Intervention: Paracetamol (1g intravenous infusion)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Parecoxib (40mg intravenous infusion)
Number of subjects: 203
Study: 34951331

Group type: EXPERIMENTAL
Intervention: PTES-K (Korean Version of the Perceived Therapeutic Efficacy Scale)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: PTES-K
Number of subjects: 108
Study: 32787809

Group type: EXPERIMENTAL
Intervention: Self-management behaviors (medication therapy, diet therapy, exercise, tobacco and alcohol avoidance, stress reduction, self-monitoring/self-care)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Self-management behaviors (diet therapy)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Self-management behaviors (self-monitoring/self-care)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Self-management behaviors (exercise)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Self-management behaviors (tobacco and alcohol avoidance)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Self-management behaviors (medication therapy)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Self-efficacy as a mediator
Number of subjects: 148
Study: 36028977

Group type: EXPERIMENTAL
Intervention: Social media use (Instagram®) for 30 minutes before training
Number of subjects: 18

Group type: COMPARATOR
Intervention: Watching TV for 30 minutes before training (Control)
Number of subjects: 18
Study: 33538782

Group type: EXPERIMENTAL
Intervention: MRI-targeted biopsy (MRI-TB)
Number of subjects: 453

Group type: COMPARATOR
Intervention: Systematic 12-core TRUS biopsy
Number of subjects: 453
Study: 35486131

Group type: EXPERIMENTAL
Intervention: Bempedoic acid in combination with ezetimibe
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bempedoic acid in addition to statins
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bempedoic acid
Number of subjects: 0
Study: 34850039

Group type: EXPERIMENTAL
Intervention: Recombinant zoster vaccine (RZV)
Number of subjects: 160
Study: 35277986

Group type: EXPERIMENTAL
Intervention: clinician + self‐determined monitoring
Number of subjects: 48

Group type: COMPARATOR
Intervention: clinician‐determined monitoring
Number of subjects: 48
Study: 35623877

Group type: EXPERIMENTAL
Intervention: Morus Alba extract (300 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 33314776

Group type: EXPERIMENTAL
Intervention: Percutaneous Transforaminal Endoscopic Discectomy (PTED)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Open Fenestration Discectomy (OFD)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Both PTED and OFD
Number of subjects: 136
Study: 35142231

Group type: EXPERIMENTAL
Intervention: Standing for 15 minutes
Number of subjects: 15
Study: 32144511

Group type: EXPERIMENTAL
Intervention: Transcranial photobiomodulation using 945-nm LEDs for 1 min and 25 s (9.35 J/cm2)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo group (device off)
Number of subjects: 22
Study: 35758257

Group type: EXPERIMENTAL
Intervention: Debriefing
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Feedback
Number of subjects: 45
Study: 35304155

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 2g to 4g per day
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 35179454

Group type: EXPERIMENTAL
Intervention: Behavioral intervention to improve skin and needle hygiene
Number of subjects: 252
Study: 34380636

Group type: EXPERIMENTAL
Intervention: HER2 positive (IHC 3+)
Number of subjects: 755

Group type: EXPERIMENTAL
Intervention: HER2 positive DCIS
Number of subjects: 755

Group type: COMPARATOR
Intervention: HER2 negative DCIS
Number of subjects: 755
Study: 32579195

Group type: EXPERIMENTAL
Intervention: Colchicine with standard medical treatment
Number of subjects: 105

Group type: COMPARATOR
Intervention: Standard medical treatment
Number of subjects: 105
Study: 36065050

Group type: EXPERIMENTAL
Intervention: RAS‐AHM
Number of subjects: 712
Study: 33471547

Group type: EXPERIMENTAL
Intervention: Progressive active exercise therapy (PR)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Limited passive exercise therapy (UC)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Both groups (PR and UC)
Number of subjects: 82
Study: 32540337

Group type: EXPERIMENTAL
Intervention: Cetuximab consolidation (500 mg/m2 biweekly × 6)
Number of subjects: 63

Group type: COMPARATOR
Intervention: No further treatment (control group)
Number of subjects: 63
Study: 32966574

Group type: EXPERIMENTAL
Intervention: RBX7455 (4 capsules twice daily for 4 days)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: RBX7455 (4 capsules twice daily for 2 days)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: RBX7455 (2 capsules twice daily for 2 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: RBX7455
Number of subjects: 30
Study: 33513054

Group type: EXPERIMENTAL
Intervention: Direct brain cooling at 32°C
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 14
Study: 35107188

Group type: EXPERIMENTAL
Intervention: Colchicine in combination with standard care
Number of subjects: 202

Group type: COMPARATOR
Intervention: Standard care only
Number of subjects: 202
Study: 33400027

Group type: EXPERIMENTAL
Intervention: reTAPP (repeated transabdominal preperitoneal laparoscopic repair)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Conventional open repair (Lichtenstein technique)
Number of subjects: 46
Study: 35964114

Group type: EXPERIMENTAL
Intervention: Children's Health Activity Motor Program-Afterschool Program (CHAMP-ASP)
Number of subjects: 264

Group type: COMPARATOR
Intervention: Comparison Afterschool Program (ASP)
Number of subjects: 264
Study: 34480720

Group type: EXPERIMENTAL
Intervention: Needlescopic surgery (NEED)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional laparoscopy (LAP)
Number of subjects: 30
Study: 33023357

Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 2401

Group type: COMPARATOR
Intervention: Etanercept
Number of subjects: 2401

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2401
Study: 34062263

Group type: EXPERIMENTAL
Intervention: Polyphenols as adjunctive treatments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Polyphenols
Number of subjects: 0
Study: 32769849

Group type: EXPERIMENTAL
Intervention: CMX-2043 (2.4 mg/kg)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study: 36197656

Group type: COMPARATOR
Intervention: Completely successful belief about antibiotics
Number of subjects: 776

Group type: COMPARATOR
Intervention: Intermediate belief about antibiotics
Number of subjects: 776
Study: 33517830

Group type: EXPERIMENTAL
Intervention: Awareness of influenza vaccine availability
Number of subjects: 1377

Group type: EXPERIMENTAL
Intervention: Awareness of free influenza vaccine availability
Number of subjects: 1377

Group type: EXPERIMENTAL
Intervention: Confidence in vaccine efficacy
Number of subjects: 1377

Group type: EXPERIMENTAL
Intervention: Confidence in vaccine safety
Number of subjects: 1377
Study: 32835919

Group type: EXPERIMENTAL
Intervention: Fennel seed extract (200 mg per capsule, 4 capsules daily for 2 weeks)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo (4 capsules daily for 2 weeks)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Fennel seed extract
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 35296528

Group type: EXPERIMENTAL
Intervention: Nurse-led patient education intervention (face-to-face education by a nurse at baseline and 3 months later)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Nurse-led patient education intervention
Number of subjects: 129
Study: 32574006

Group type: EXPERIMENTAL
Intervention: CNP group
Number of subjects: 302

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 302
Study: 34668963

Group type: EXPERIMENTAL
Intervention: Laparoscopic distal gastrectomy (n=528)
Number of subjects: 1056

Group type: COMPARATOR
Intervention: Open distal gastrectomy (n=528)
Number of subjects: 1056

Group type: EXPERIMENTAL
Intervention: Laparoscopic distal gastrectomy
Number of subjects: 1056

Group type: COMPARATOR
Intervention: Open distal gastrectomy
Number of subjects: 1056
Study: 34110580

Group type: EXPERIMENTAL
Intervention: Ringer lactate solution (RLS)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Normal saline solution (NSS)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sterofundin
Number of subjects: 42
Study: 616788753

Group type: EXPERIMENTAL
Intervention: Resistance training for 8 weeks, 3 sessions per week at 50-70% of 1RM
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study: 33420104

Group type: EXPERIMENTAL
Intervention: Bendiocarb exposure during pregnancy
Number of subjects: 0
Study: 32876695

Group type: EXPERIMENTAL
Intervention: Dexamethasone (20 mg IV daily for 5 days or 10 mg IV daily for 5 days until ICU discharge) plus standard care
Number of subjects: 299

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 299
Study: 36346783

Group type: EXPERIMENTAL
Intervention: PediQUEST Response
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual Cancer Care
Number of subjects: 200
Study: 34236794

Group type: EXPERIMENTAL
Intervention: Low-thermal plasma kinetic cautery (PKC)
Number of subjects: 258

Group type: COMPARATOR
Intervention: Conventional monopolar electrosurgery (CMES)
Number of subjects: 258
Study: 33160571

Group type: EXPERIMENTAL
Intervention: Drug-coated balloons (DCB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Drug-eluting stents (DES)
Number of subjects: 0
Study: 33168504

Group type: EXPERIMENTAL
Intervention: Disposable circumcision suture device (DCSD)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Conventional circumcision (CC)
Number of subjects: 236
Study: 34556856

Group type: EXPERIMENTAL
Intervention: Valsartan (320 mg daily in adults; 80-160 mg daily in children)
Number of subjects: 178
Study: 35345654

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine combined intravenous anesthesia
Number of subjects: 285

Group type: COMPARATOR
Intervention: Conventional intravenous anesthesia
Number of subjects: 285
Study: 32161953

Group type: EXPERIMENTAL
Intervention: Infusion of ketone bodies during a hyperinsulinemic-euglycemic clamp
Number of subjects: 8

Group type: COMPARATOR
Intervention: Infusion of saline during a hyperinsulinemic-euglycemic clamp
Number of subjects: 8
Study: 34089846

Group type: EXPERIMENTAL
Intervention: Lirentelimab (AK002), an antibody against siglec-8 that depletes eosinophils and inhibits mast cells.
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Multiple biopsies (8 gastric and 4 duodenal)
Number of subjects: 88
Study: 37497068

Group type: EXPERIMENTAL
Intervention: MEntA Program based on motivational interview for adherence
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study: 35230440

Group type: EXPERIMENTAL
Intervention: Intravesical chemotherapy after TURBT
Number of subjects: 0
Study: 32028974

Group type: EXPERIMENTAL
Intervention: Bevacizumab 15 mg/kg intravenously on day 1 and gemcitabine 1000 mg/m2 intravenously on days 1 and 8 every 21 days until disease progression or unacceptable toxicity
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Bevacizumab and gemcitabine combination therapy
Number of subjects: 19
Study: 34839204

Group type: COMPARATOR
Intervention: Five-degree lateral wedge insole (LWI)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Off-the-shelf knee sleeve
Number of subjects: 17

Group type: COMPARATOR
Intervention: Knee sleeve
Number of subjects: 17

Group type: COMPARATOR
Intervention: Combined LWI and knee sleeve
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 17
Study: 33827091

Group type: EXPERIMENTAL
Intervention: 4 L/min bias gas flow
Number of subjects: 95

Group type: COMPARATOR
Intervention: 10 L/min bias gas flow
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Plasma IL-8 concentrations
Number of subjects: 95